


Asco-GI 2021 round-up - Cardiff disappoints while Arcus intrigues



Jacob Plieth

Enhertu’s additional approval this morning for Her2-positive gastric cancer coincided with the Asco-GI conference, which featured a front-line gastric cancer study of Five Prime’s bemarituzumab as a late-breaker. The green light, the first for a Her2-directed therapy for this cancer since Herceptin, will also remind investors what the Astra/Daiichi drug has to do to meet expectations: *EvaluatePharma* consensus forecasts see 2026 sales of \$4.1bn, mostly in breast cancer. Meanwhile, much of Five Prime’s data was a retread of that [toplined last November](#), and with continuing doubts about bemarituzumab’s relevance beyond FGFR2b-overexpressing cancers the stock fell 11%. Also off on Asco-GI data was Cardiff Oncology, down 31% after reminding the markets that, with four more Kras-mutant colorectal cancer subjects treated, the overall response rate to onvansertib was [still around 40%](#). Bridgebio Pharma’s infigratinib showed a 23% ORR in FGFR2-positive cholangiocarcinoma, underperforming the 36% on the [approved label of Incyte’s similarly acting Pemazyre](#). Perhaps the most intriguing dataset came from Arcus’s AB680 in front-line pancreatic cancer: 41% ORR in 17 subjects could give the company a focus beyond Tigit inhibition. Still, the study also included chemo and an anti-PD-1, so AB680’s effect is hard to tease out.

Arcus Asco-GI 2021 data: time on treatment & Recist v1.1 response



IV, intravenously; NP/Gem, nab-paclitaxel/gemcitabine; PD, progressive disease; PR, partial response; Q2W, every 2 weeks; Zim, zimberelelimab.

Clinical activity of AB680 + zimberelelimab in 1st-line pancreatic adenocarcinoma. Source: Dr Gulam Abbas Manji & Asco.

Selected data presented at the 2021 Asco-GI meeting

Project	Company	Mechanism	Setting	Detail
Bemarituzumab	Five Prime	Anti-FGFR2b	Fight study: a 1L gastric/GEJ (chemo combo)	In FGFR2b \geq 10% expressers (n=96) mPFS 14.1 vs 7.3 mth, mOS NR vs 11.1 mth
Infigratinib	Bridgebio Pharma	Anti-FGFR1-3	2L FGFR2+ve cholangio	1 CR & 24 PRs in 108 evaluable pts, mPFS 7.3mth, mOS 12.2mth
Tibsovo	Agios	Anti-IDH1	Final Claridhy study data: 2L IDH1-mut cholangio	HR 0.37 for PFS, and 0.49 for OS, both highly stat sig
AB680 + AB122	Arcus	Anti-CD79 + anti-PD-1	Arc-8 study: 1L pancreatic adenocarcinoma	7/17 PRs
Onvansertib	Cardiff Oncology	Anti-PLK1	2L Kras-mut colorectal (Avastin + chemo combo)	5/12 PRs
CYAD-101	Celyad	Allo (TIM-expressing) Car-T vs NKG2D ligands	Alloshrink study: metastatic colorectal	2/15 PRs, including 1 Kras-mutant

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2021 Evaluate Ltd.